Twist Bioscience Insider Emily Leproust Sells $1.74M in TWST Stock

Key Facts

Amid heightened scrutiny of executive dealings within the biotech sector, Emily Leproust, an insider at Twist Bioscience, sold over 49,000 shares in May 2026. According to reports, these transactions totaled approximately $1.74 million and were executed as routine executive resales via Form 144 filings. At least one of these sales was linked to a stock option originally granted in 2017.

These moves come as investors closely monitor the performance of synthetic biology firms, where Twist Bioscience competes with peers such as Ginkgo Bioworks and Pacific Biosciences. Per market data, the biotechnology sector has experienced significant volatility recently, making insider sales a key metric for assessing internal confidence levels. These transactions are typically part of pre-scheduled trading plans used by executives to diversify their holdings.

Looking at the available data, TWST shares closed recent sessions as traders pivot toward macroeconomic catalysts, including the CB Consumer Confidence index which reached 93.1 on May 26, 2026, according to economic calendar data. Investors should watch for technical support levels following these sales, especially as risk appetite in the growth sector remains sensitive to broader economic shifts.